aldafermin
ngm biopharmaceuticals
['$ngm']
ngm bio announces presentation of data from phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (ibs-d) and bile acid malabsorption (bam) at digestive disease week 2023 $ngm 
Real-Time News, Market Data, Insider Trades, and Stock Quotes for Biotech, Pharma, Medical, and Healthcare Stocks @ https://t.co/Oqp6BRBKy2